Protocol 156-03-236: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure.

Trial Profile

Protocol 156-03-236: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Chronic heart failure; Heart failure
  • Focus Therapeutic Use
  • Acronyms EVEREST
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 15 Nov 2017 Results of sudden cardiac death risk after hospitalisation presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 07 Oct 2015 Results published in the European Journal of Heart Failure
    • 02 May 2012 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top